Reference
- LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med20123661382139222452356
- LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol2014
- LedermannJHarterPGourleyCHealth-related quality of life (HRQOL) during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSROC) and a BRCA mutation (BRCAM) [abstract]Ledermann J, Harter P, Gourley C et alAnn Oncol201425
- Basen-EngquistKBodurka-BeversDFitzgeraldMAReliability and validity of the functional assessment of cancer therapy-ovarianJ Clin Oncol2001191809181711251013
- Al-KakkakIBorrillJMurphyEA systematic review of health state utility values for advanced ovarian cancerThe International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress14 Nov 82014
- PerrenTJSwartAMPfistererJA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med20113652484249622204725
- MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancerJ Clin Oncol2010283107311420516432
- KrasnerCNPovedaAHerzogTJPatient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD aloneGynecol Oncol201212716116722765965
- HessLMBradyWEHavrileskyLJComparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group studyGynecol Oncol201312817518023123576
- PickardASRaySGanguliACellaDComparison of FACT-and EQ-5D-based utility scores in cancerValue Health20121530531122433762
- University of OxfordHealth Economics Research Centre database of mapping studies http://www.hercoxacuk/downloads/mappingdatabase [serial online]2013
- R Core TeamR: A language and environment for statistical computing2015 Available from https://www.R-project.org
- PickardASNearyMPCellaDEstimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth Qual Life Outcomes200757018154669
- PinheiroJBatesDDebRoySSarkarDnlme: Linear and Nonlinear Mixed Effects Models2015 Available from: http://CRAN.R-project.org/package=nlme
- AskewRLSwartzRJXingYMapping FACT-melanoma quality-of-life scores to EQ-5D health utility weightsValue Health20111490090621914512
- WuEQMulaniPFarrellMHSleepDMapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patientsValue Health20071040841417888106
- LongworthLYangYYoungTUse of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and surveyHealth Technol Assess201418122424524660
- CheungYBThumbooJGaoFMapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility indexValue Health20091237137618783392
- DobrezDCellaDPickardASLaiJSNickolovAEstimation of patient preference-based utility weights from the functional assessment of cancer therapy - generalValue Health20071026627217645681
- PickardASDe LeonMCKohlmannTCellaDRosenbloomSPsychometric comparison of the standard EQ-5D to a 5 level version in cancer patientsMed Care20074525926317304084
- National Institute for Health and Care ExcellenceTA222: Trabectedin for the treatment of relapsed ovarian cancer2011
- National Institute of Health and Care ExcellenceTA284: Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of ovarian cancer2013
- PovedaAVergoteITjulandinSTrabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trialAnn Oncol201122394820643862
- Decision Support Unit at the National Institute for Health and Care ExcellenceTechnical Support Document 10: The use of mapping methods to estimate health state utility values http://www.nicedsu.org.uk/TSD%2010%20mapping%20FINAL.pdf [serial online]2014
- DolanPModeling valuations for EuroQol health statesMed Care199735109511089366889
- LuoNJohnsonJCoonsSJUsing instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instrumentsMed Care20104836537120355266
- BedardGZengLLamHMeaningful change in oncology quality-of-life instruments: a systematic literature reviewExpert Rev Pharmacoecon Outcomes Res20121247548322971034